摘要
背景:基因治疗代表核酸聚合物向患者细胞的治疗性递送,目的是治疗潜在的疾病。在过去的二十年中,由于更好地理解了各种疾病的病理生理学基础以及基因转移生物技术的发展,这种新疗法已经取得了实质性的进展。由于血眼屏障所提供的免疫特权,直接观察,进入和局部治疗细胞的能力以及所需的最小量的载体,眼睛尤其代表了这种治疗的合适目标器官。因此,这个领域正在进行几项临床试验,这并不令人惊讶。 目的:这次审查的目的是提供基因治疗视网膜疾病的最新进展,讨论治疗策略,载体设计和手术技巧的差异。 方法:在PubMed,ClinicalTrials.gov和Home Genetic Reference上进行研究。此外,我们还利用网络数据库进行视网膜疾病遗传学,罕见疾病和孤儿药物门户以及NCBI数据库在线孟德尔遗传研究。出版物的语言没有任何限制。 结果:我们提供了目前Leber先天性黑蒙2型,脉络膜血症,Stargardt病,色盲和青少年X连锁视网膜劈裂等遗传性视网膜疾病的现行临床试验结果。我们还说明了这种治疗更为常见的眼部疾病如年龄相关性黄斑变性和糖尿病性视网膜病的新方法。 结论:基因治疗不仅治疗罕见的遗传性视网膜疾病,而且还有更常见的视网膜病变,是治疗新兴的治疗方法。
关键词: 基因治疗,眼,视网膜,病毒载体,给药途径,萎缩。
Current Gene Therapy
Title:The Role of Gene Therapy in the Treatment of Retinal Diseases: A Review
Volume: 17 Issue: 3
关键词: 基因治疗,眼,视网膜,病毒载体,给药途径,萎缩。
摘要: Background: Gene therapy represents the therapeutic delivery of nucleic acid polymers into patient cells with the aim of treating an underlying disease. Over the past 2 decades this new therapy has made substantial progress owing to better understanding of the pathobiologic basis of various diseases coupled with growth of gene transfer biotechnologies. The eye, in particular, represents a suitable target for such therapy due to the immune privilege provided by the blood-ocular barrier, the ability to directly visualize, access and locally treat the cells and the minimal amount of vector needed given the size of this organ. It is not surprising therefore that several clinical trials are now ongoing in this field.
Objective: The purpose of this review was to provide an update on gene therapy for retinal diseases, discussing differences in treatment strategies, vector designs and surgical techniques.
Method: Research was performed on PubMed, ClinicalTrials.gov, and Home Genetic Reference. We additionally utilized the internet database for genetics of retinal diseases, the portal for rare diseases and orphan drugs and the NCBI database Online Mendelian Inheritance in Man. No restriction was applied on the language of publications.
Results: We present the available results of current active clinical trials for inherited retinal disease such as Leber's congenital amaurosis type 2, choroideremia, Stargardt disease, achromatopsia and juvenile X-linked retinoschisis. We also illustrate a new approach of this therapy for the treatment of much more common ocular diseases such as age-related macular degeneration and diabetic retinopathy.
Conclusion: Gene therapy represents an emerging and promising therapeutic approach for the treatment not only of rare inherited retinal diseases but also much more common retinal pathologies.
Export Options
About this article
Cite this article as:
The Role of Gene Therapy in the Treatment of Retinal Diseases: A Review, Current Gene Therapy 2017; 17 (3) . https://dx.doi.org/10.2174/1566523217666171116170040
DOI https://dx.doi.org/10.2174/1566523217666171116170040 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements